UOC
INBX

UBS O'Connor’s Inhibrx, Inc. Common Stock INBX Stock Holding History

UBS O'Connor’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-33,448
Closed -$614K – 672
2023
Q3 		$614K Hold
33,448
– – 0.01% 382
2023
Q2 		$868K Buy
33,448
+1,648
+5% +$38.5K 0.02% 397
2023
Q1 		$600K Buy
+31,800
New +$740K 0.01% 449
2022
Q4 		– Sell
-71,297
Closed -$1.28M – 929
2022
Q3 		$1.28M Sell
71,297
-13,753
-16% -$248K 0.01% 714
2022
Q2 		$965K Buy
+85,050
New +$1.25M 0.01% 773

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS O'Connor's INBX Position: Q4 2023 in Review

UBS O'Connor sold out of Inhibrx, Inc. Common Stock (INBX) in Q4 2023, closing a stake of 33,448 shares — an estimated $614K sold.

UBS O'Connor first reported a position in INBX in Q2 2022 and held it in 5 quarters. The position peaked at $1.28M in Q3 2022. 127 funds tracked by Wall St. Rank hold INBX as of Q4 2023.

  • UBS O'Connor reported no remaining Inhibrx, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • UBS O'Connor sold 33,448 Inhibrx, Inc. Common Stock shares in Q4 2023, an estimated $614K.
  • UBS O'Connor first reported a position in Inhibrx, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
  • UBS O'Connor's Inhibrx, Inc. Common Stock position peaked at $1.28M in Q3 2022.
  • 127 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.